View Filing Data

Intangible Assets, net

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Note 9 — Intangible Assets, net

Intangible assets, less accumulated amortization, consisted of the following as of:

	Estimated Useful Life	December 31, 2023			December 31, 2022
Defensive asset	60 months	$	2,105		$	2,105
Laboratory licenses and certifications and laboratory information management software	24 months		3,200			3,200
Other	1 year		70			70
Total Intangible assets			5,375			5,375
Less Accumulated Amortization			(3,951	)		(1,930	)
Intangible Assets, net		$	1,424		$	3,445

The defensive technology intangible asset was recognized upon its acquisition of CapNostics, an unrelated third-party, for total purchase consideration paid on the October 5, 2021 acquisition date of approximately $2.1 million in cash. The CapNostics transaction was accounted for as an asset acquisition, resulting in the recognition of the defensive technology intangible asset. The defensive technology intangible asset is being amortized on a straight-line basis over an expected useful life 60 months commencing on the acquisition date.

The intangible assets recognized under the APA-RDx are the laboratory licenses and certifications, inclusive of a CLIA certification, CAP accreditation, and clinical laboratory licenses for five (5) U.S. States transfer to the Company from RDx, and a laboratory information management software perpetual-use royalty-free license granted under the APA-RDx, with such intangible asset having a useful life of twenty-four months commencing on the APA-RDx February 25, 2022 transaction date.

Amortization expense of the intangible assets discussed above was $2,021 and $1,784 for the years ended December 31, 2023 and 2022, respectively, and is included in amortization of acquired intangible assets in the accompanying consolidated statements of operations. As of December 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:


2024	$	688
2025		421
2026		315
Total	$	1,424

Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 7 months 6 days	5 years 9 months 18 days
Expected stock price volatility	88.00%	88.00%
Risk free interest rate	3.80%	2.20%
Expected dividend yield
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 7 months 6 days	5 years 7 months 6 days
Expected stock price volatility	74.00%	71.00%
Risk free interest rate	3.90%	2.10%
Expected dividend yield

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Leases (Tables)

12 Months Ended

Dec. 31, 2023

Leases

Schedule of Lease Expense

The components of lease expense were as follows:

Schedule of Lease Expense

	2023		2022
	Years Ended December 31,
	2023		2022
Operating lease cost	$	1,871	$	1,174
Short-term lease cost		89		191
Variable lease cost		113		52
Total lease cost	$	2,073	$	1,417

Schedule of Future Minimum Lease Payments for Operating Leases

The Company’s future lease payments as of December 31, 2023, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s consolidated balance sheets are as follows:


2024	$	1,854
2025		835
2026		787
2027		617
2028		471
Thereafter		848
Total lease payments	$	5,412
Less: imputed interest		(887	)
Present value of lease liabilities	$	4,525

Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases

Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows:

	2023			2022
	Years Ended December 31,
	2023			2022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	1,563		$	1,078
Non-cash investing and financing activities
Right-of-use assets obtained in exchange for new operating lease liabilities	$	2,728		$	3,949
Weighted-average remaining lease term - operating leases (in years)		4.62			2.84
Weighted-average discount rate - operating leases		7.875	%		7.875	%

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 19,639	$ 39,744
Accounts receivable	61	17
Inventory	278	111
Prepaid expenses, deposits, and other current assets	4,520	4,054
Total current assets	24,498	43,926
Fixed assets, net	1,783	2,451
Operating lease right-of-use assets	4,267	3,037
Intangible assets, net	1,424	3,445
Other assets	1,147	1,121
Total assets	33,119	53,980
Current liabilities:
Accounts payable	1,786	2,704
Accrued expenses and other current liabilities	6,626	3,705
Operating lease liabilities, current portion	1,565	1,141
Senior Secured Convertible Notes - at fair value	44,200	33,650
Total current liabilities	54,177	41,200
Operating lease liabilities, less current portion	2,960	1,846
Total liabilities	57,137	43,046
Commitments and contingencies (Note 11)
Stockholders’ Equity:
Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,305,213 at December 31, 2023 and 1,205,759 shares at December 31, 2022	2,993	2,695
Common stock, $0.001 par value. Authorized, 50,000,000 shares; 8,578,505 and 6,300,703 shares outstanding as of December 31, 2023 and December 31, 2022, respectively	9	6
Additional paid-in capital	237,600	216,195
Accumulated deficit	(294,433)	(228,169)
Treasury stock		(408)
Total PAVmed Inc. Stockholders’ Equity (Deficit)	(53,831)	(9,681)
Noncontrolling interests	29,813	20,615
Total Stockholders’ Equity (Deficit)	(24,018)	10,934
Total Liabilities and Stockholders’ Equity (Deficit)	$ 33,119	$ 53,980

Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Noncontrolling Interest [Member]	Series B Convertible Preferred Stock [Member]	Total
Beginning balance at Dec. 31, 2021	$ 2,419	$ 5	$ 198,152	$ (138,910)		$ 17,752		$ 79,418
Beginning balance, shares at Dec. 31, 2021	1,113,919	5,757,856
Dividends declared - Series B Convertible Preferred Stock	$ 276			(276)			$ 276
Dividends declared - series B convertible preferred stock, shares	91,885						91,885
Vest - restricted stock awards		$ 1	(1)
Vest - restricted stock awards, shares		36,112
Conversions - Series B Convertible Preferred Stock
Conversions - Series B Convertible Preferred Stock, shares	(45)	3
Conversions - majority-owned subsidiary common stock - Senior Secured Convertible Note
Purchase - Employee Stock Purchase Plan			218		140			358
Purchase - Employee Stock Purchase Plan, shares		12,950
Impact of subsidiary equity transactions			(28)			28
Issuance - majority-owned subsidiary common stock - Settlement APA-RDx - Installment Payment						653		653
Issuance - majority-owned subsidiary preferred stock
Stock-based compensation - PAVmed Inc.			5,666					5,666
Stock-based compensation - majority-owned subsidiaries						13,866		13,866
Treasury stock					(548)			(548)
Treasury stock, shares		12,592
Net Loss				(88,983)		(14,255)		(103,238)
Issue common stock - PAVM ATM Facility			79					79
Issue common stock - PAVM ATM Facility, shares		7,082
Exercise - Series Z warrants
Exercise - Series Z warrants, shares		1
Conversions - Senior Secured Convertible Note			11,807					11,807
Conversions - Senior Secured Convertible Note, shares		479,291
Exercise - stock options			302					302
Exercise - stock options, shares		20,000
Exercise - stock options of majority-owned subsidiary						695		695
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan						109		109
Issuance - majority-owned subsidiary common stock - Committed Equity Facility, net of financing charges						1,767		1,767
Treasury stock, shares		(12,592)
Ending balance at Dec. 31, 2022	$ 2,695	$ 6	216,195	(228,169)	(408)	20,615		10,934
Ending balance, shares at Dec. 31, 2022	1,205,759	6,300,703
Dividends declared - Series B Convertible Preferred Stock	$ 298			(298)			$ 298
Dividends declared - series B convertible preferred stock, shares	99,454						99,454
Issue common stock - PAVM ATM Facility		$ 1	1,823					1,824
Issue common stock - PAVM ATM Facility, shares		321,288
Vest - restricted stock awards
Vest - restricted stock awards, shares		6,666
Conversions - Series B Convertible Preferred Stock		$ 2	10,000					10,002
Conversions - Series B Convertible Preferred Stock, shares		1,745,824
Conversions - majority-owned subsidiary common stock - Senior Secured Convertible Note						167		167
Purchase - Employee Stock Purchase Plan			198		60			258
Purchase - Employee Stock Purchase Plan, shares		45,893
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan						551		551
Issuance - majority-owned subsidiary common stock - At-The-Market Facility, net of financing charges						284		284
Impact of subsidiary equity transactions			1,983			(1,983)
Issuance - majority-owned subsidiary common stock - Settlement APA-RDx - Installment Payment						713		713
Issuance - vendor service agreement			601			147		748
Issuance - vendor service agreement, shares		100,000
Issuance - majority-owned subsidiary preferred stock						18,625		18,625
Issuance of shares related to reverse stock split
Issuance of shares related to reverse stock split, shares		45,541
Incremental value from Z Warrant modification			1,791	(1,791)
Stock-based compensation - PAVmed Inc.			4,255					4,255
Stock-based compensation - majority-owned subsidiaries			1,102			5,782		6,884
Treasury stock			(348)		348
Treasury stock, shares		12,590
Net Loss				(64,175)		(15,088)		(79,263)
Treasury stock, shares		(12,590)
Ending balance at Dec. 31, 2023	$ 2,993	$ 9	$ 237,600	$ (294,433)		$ 29,813		$ (24,018)
Ending balance, shares at Dec. 31, 2023	1,305,213	8,578,505

Schedule of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases
Operating lease cost	$ 1,871	$ 1,174
Short-term lease cost	89	191
Variable lease cost	113	52
Total lease cost	$ 2,073	$ 1,417

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

Note 10 — Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following items as of:

	December 31, 2023		December 31, 2022
Compensation and Employee Benefits	$	2,507	$	1,940
CWRU Amended License Agreement - Royalty fee		96		10
Operating expenses		3,246		1,755
Other current liabilities		777		—
Total accrued expenses and other current liabilities	$	6,626	$	3,705

The “Compensation and Employee Benefits” includes: discretionary bonus payments to employees; unused employee vacation time; and employee payroll deductions related to the PAVmed Inc. Employee Stock Purchase Plan (“PAVmed Inc. ESPP”). See Note 14, Stock-Based Compensation, for additional information on the PAVmed Inc. ESPP.

Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total stock-based compensation expense	$ 11,139	$ 19,532
Lucid Diagnostics Inc [Member]
Total stock-based compensation expense	6,822	14,991
Cost of Revenue [Member]
Total stock-based compensation expense	122	16
Selling and Marketing Expense [Member]
Total stock-based compensation expense	1,715	2,464
General and Administrative Expense [Member]
Total stock-based compensation expense	7,935	16,001
Research and Development Expense [Member]
Total stock-based compensation expense	1,367	1,051
Lucid Diagnostics Inc 2018 Equity Plan [Member] \| Cost of Revenue [Member]
Total stock-based compensation expense	63	13
Lucid Diagnostics Inc 2018 Equity Plan [Member] \| Selling and Marketing Expense [Member]
Total stock-based compensation expense	948	968
Lucid Diagnostics Inc 2018 Equity Plan [Member] \| General and Administrative Expense [Member]
Total stock-based compensation expense	4,455	12,691
Lucid Diagnostics Inc 2018 Equity Plan [Member] \| Research and Development Expense [Member]
Total stock-based compensation expense	296	187
PAVmed Inc 2014 Equity Plan [Member] \| Cost of Revenue [Member]
Total stock-based compensation expense	37	3
PAVmed Inc 2014 Equity Plan [Member] \| Selling and Marketing Expense [Member]
Total stock-based compensation expense	463	654
PAVmed Inc 2014 Equity Plan [Member] \| General and Administrative Expense [Member]
Total stock-based compensation expense	173	262
PAVmed Inc 2014 Equity Plan [Member] \| Research and Development Expense [Member]
Total stock-based compensation expense	$ 387	$ 213

Schedule of Restricted Stock Award Activity (Details) (Parenthetical) - shares	1 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reverse stock split, description	1-for-15 reverse stock split
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reverse stock split, description		1-for-15 reverse stock split
Granted restricted stock, shares			6,666
Vested restricted stock, shares		6,666
2018 Equity Plan [Member] \| Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted restricted stock, shares			50,000
Vested restricted stock, shares		50,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2023
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Leases (Details Narrative) - USD ($) $ in Thousands	1 Months Ended
Leases (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease, right-of-use assets		$ 4,267	$ 3,037
Operating lease obligations		4,525	2,987
Operating lease, liability, current		1,565	1,141
Operating lease liability noncurrent		$ 2,960	$ 1,846
Payments for rent	$ 3,200
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lessee operating lease description	The lease agreement term is from the September 15, 2022 execution date to the date which is seven years and eight months from the lease commencement date, with the rent abated for the first eight months of the lease term.

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Compensation and Employee Benefits	$ 2,507	$ 1,940
CWRU Amended License Agreement - Royalty fee	96	10
Operating expenses	3,246	1,755
Other current liabilities	777
Total accrued expenses and other current liabilities	$ 6,626	$ 3,705

Debt (Tables)

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Summary of Outstanding Debt

The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows:

Summary of Outstanding Debt

	Contractual Maturity Date	Stated Interest Rate			Conversion Price per Share		Face Value Principal Outstanding		Fair Value
April 2022 Senior Convertible Note	April 4, 2025		7.875	%	$	75.00	$	17,602	$	19,000
September 2022 Senior Convertible Note	September 8, 2025		7.875	%	$	75.00	$	9,062	$	11,250
Lucid March 2023 Senior Convertible Note	March 21, 2025		7.875	%	$	5.00	$	11,019	$	13,950
Balance as of December 31, 2023							$	37,683	$	44,200

	Contractual Maturity Date	Stated Interest Rate			Conversion Price per Share		Face Value Principal Outstanding		Fair Value
April 2022 Senior Convertible Note	April 4, 2025		7.875	%	$	75.00	$	21,497	$	22,000
September 2022 Senior Convertible Note	September 6, 2025		7.875	%	$	75.00	$	11,250	$	11,650
Balance as of December 31, 2022							$	32,747	$	33,650

Schedule of Changes in Fair Value of Debt

The changes in the fair value of debt during the year ended December 31, 2023 is as follows:

	April 2022 Senior Convertible Note			September 2022 Senior Convertible Note			Lucid March 2023 Senior Convertible Note			Sum of Balance Sheet Fair Value Components			Other Income (expense)
Fair Value - December 31, 2022	$	22,000		$	11,650		$	—		$	33,650		$	—
Face value principal – issue date		—			—			11,111			11,111			—
Fair value adjustment – issue date		—			—			789			789			(789	)
Installment repayments – common stock		(3,895	)		(2,188	)		(92	)		(6,175	)		—
Non-installment payments – common stock		(249	)		(114	)		(49	)		(412	)		—
Change in fair value		1,144			1,902			2,191			5,237			(5,237	)
Fair Value at December 31, 2023	$	19,000		$	11,250		$	13,950		$	44,200			-
Other Income (Expense) - Change in fair value – year ended December 31, 2023													$	(6,026	)

The changes in the fair value of debt during the year ended December 31, 2022 is as follows:

	April 2022 Senior Convertible Note			September 2022 Senior Convertible Note			Sum of Balance Sheet Fair Value Components			Other Income (expense)
Fair Value - December 31, 2021	$	—		$	—		$	—		$	—
Fair Value - Beginning	$	—		$	—		$	—		$	—
Face value principal – issue date		27,500			11,250			38,750			—
Fair value adjustment – issue date		2,600			950			3,550			(3,550	)
Installment repayments – common stock		(6,003	)		—			(6,003	)		—
Non-installment payments – common stock		(370	)		—			(370	)		—
Change in fair value		(1,727	)		(550	)		(2,277	)		2,277
Fair Value at December 31, 2022	$	22,000		$	11,650		$	33,650			-
Fair Value - Ending	$	22,000		$	11,650		$	33,650			-
Other Income (Expense) - Change in fair value – year ended December 31, 2022										$	(1,273	)

Income Taxes

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Income Taxes

Note 18 — Income Taxes

Income tax (benefit) expense for respective periods noted is as follows:

	2023			2022
	Years Ended December 31,
	2023			2022
Current
Federal, State and Local	$	—		$	—
Deferred
Federal		(16,789	)		(24,265	)
State and Local		(19,323	)		11,124
Current and Deferred tax (benefit) expense		(36,112	)		(13,141	)
Less: Valuation allowance reserve		36,112			13,141
Income tax expense (benefit)	$	—		$	—

The reconciliation of the federal statutory income tax rate to the effective income tax rate for the respective period noted is as follows:

	2023			2022
	Years Ended December 31,
	2023			2022
U.S. federal statutory rate		21.0	%		21.0	%
U.S. state and local income taxes, net of federal benefit		6.1	%		6.6	%
Permanent differences		(2.7	)%		(1.0	)%
Tax credits		2.2	%		1.3	%
Revaluation of state deferred taxes		—	%		(15.2	)%
Federal deferred true-up		5.8	%		—	%
State deferred true-up		13.2	%		—	%
Valuation allowance		(45.6	)%		(12.7	)%
Effective tax rate		—	%		—	%

Note 18 — Income Taxes - continued

The tax effects of temporary differences which give rise to the net deferred tax assets for the respective period noted is as follows:

	2023			2022
	Years Ended December 31,
	2023			2022
Deferred Tax Assets
Net operating loss	$	67,786		$	37,032
Debt issue costs		537			922
Stock-based compensation expense		12,304			11,105
Lease liabilities		1,266			836
Research and development expenditures		8,234			6,193
Research and development tax credit carryforwards		3,481			1,719
Accrued expenses		385			311
Section 195 deferred start-up costs		17			15
Depreciation & amortization	$	800		$	221
Deferred tax assets	$	94,810		$	58,354

Deferred Tax Liabilities
Operating lease right-of-use assets		(1,194	)		(850	)
Depreciation		—			—
Patent licenses		—			—
Deferred Tax Liabilities	$	(1,194	)	$	(850	)

Deferred tax assets, net of deferred tax liabilities		93,616			57,504
Less: valuation allowance		(93,616	)		(57,504	)
Deferred tax assets, net after valuation allowance	$	—		$	—

Note 18 — Income Taxes - continued

Deferred tax assets and deferred tax liabilities resulting from temporary differences are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of the change in the tax rate is recognized as income or expense in the period the change in tax rate is enacted.

As required by FASB ASC Topic 740, Income Taxes, (“ASC 740), a “more-likely-than-not” criterion is applied when assessing the estimated realization of deferred tax assets through their utilization to reduce future taxable income, or with respect to a deferred tax asset for tax credit carryforward, to reduce future tax expense. A valuation allowance is established, when necessary, to reduce deferred tax assets, net of deferred tax liabilities, when the assessment indicates it is more-likely-than-not, the full or partial amount of the net deferred tax asset will not be realized. Accordingly, the Company evaluated the positive and negative evidence bearing upon the estimated realizability of the net deferred tax assets, and based on the Company’s history of operating losses, concluded it is more-likely-than-not the deferred tax assets will not be realized, and therefore recognized a valuation allowance reserve equal to the full amount of the deferred tax assets, net of deferred tax liabilities, as of December 31, 2023 and 2022. As of December 31, 2023 and 2022, the deferred tax asset valuation allowance increased by $36,112 and $13,141, respectively.

The Company has total estimated federal net operating loss (“NOL”) carryforward of approximately $236.3 million and $158.4 million as of December 31, 2023 and 2022, respectively, which is available to reduce future taxable income, of which approximately $13.8 million have statutory expiration dates commencing in 2037, and approximately $222.5 million which do not have a statutory expiration date. The Company has not yet conducted a formal analysis and the NOL carryforward and general business credits may be subject-to limitation under U.S. Internal Revenue Code (“IRC”) Section 382 (provided there was a greater than 50% ownership change, as computed under such IRC Section 382). The State and Local NOL carryforwards of approximately $260.0 million have statutory expiration dates commencing in 2037. The Company has total estimated research and development (“R&D”) tax credit carryforward of approximately $3.4 million as of December 31, 2023 which are available to reduce future tax expense and have statutory expiration dates commencing in 2037.

The Company files income tax returns in the United States in federal and applicable state and local jurisdictions. The Company’s tax filings for the years 2017 and thereafter each remain subject to examination by taxing authorities. The Company’s policy is to record interest and penalties related to income taxes as part of its income tax provision. The Company has not recognized any penalties or interest related to its income tax provision.

In August 2022, the U.S. Congress passed the Inflation Reduction Act, which included a corporate minimum tax on book earnings of 15%, an excise tax on corporate share repurchases of 1%, and certain climate change and energy tax credit incentives. The adoption of a corporate minimum tax of 15% is not expected to impact PAVmed’s effective tax rate. The excise tax of 1% on corporate share buybacks will not have an impact on the Company’s effective tax rate.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Revenue from Contracts with Customers (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenues	$ 2,452	$ 377
Monthly fees	100
Cost of revenue	$ 6,420	$ 3,614

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Noncontrolling Interest (Details Narrative) - USD ($)								1 Months Ended	12 Months Ended
Noncontrolling Interest (Details Narrative) - USD ($)	Mar. 15, 2024	Mar. 13, 2024	Feb. 15, 2024	Jan. 26, 2024	Jan. 15, 2024	Oct. 17, 2023	Mar. 07, 2023	Nov. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 12, 2024
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock shares outstanding									8,578,505	6,300,703
Issuance of shares value									$ 1,824,000
Gross proceeds									$ 18,625,000
Veris Health Inc [Member] \| Unrelated Third Parties [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Investment ownership percentage									19.56%
Veris Health Inc [Member] \| Parent Company [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Investment ownership percentage									80.44%
Series A Preferred Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Sale of stock, transaction value							$ 13,625,000
Lucid Series A-1 Preferred Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Gross proceeds, sale of shares						$ 5,000,000.0
Series A-1 Preferred Stock [Member] \| Subsequent Event [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of shares issued, additional	5,670	5,670
Gross proceeds	$ 5,670,000	$ 5,670,000
Series B Convertible Preferred Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Dividend percentage									8.00%
Series B Convertible Preferred Stock [Member] \| Subsequent Event [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of shares issued, additional		44,285
Gross proceeds, sale of shares		$ 18,100,000
Series A-1 and Series B Preferred Stock [Member] \| Subsequent Event [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Conversion price											$ 1.2444
Lucid Series A and Lucid Series A-1 Preferred Stock [Member] \| Subsequent Event [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Outstanding shares, percentage		100.00%
Series A Convertible Preferred Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of shares issued, additional							13,625
Issuance of shares value							$ 1,000
Preferred shares conversion price							$ 1.394
Dividend percentage							20.00%
Series A1 Convertible Preferred Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of shares issued, additional						5,000
Preferred shares conversion price						$ 1.2592
Common Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of shares issued, additional									321,288
Issuance of shares value									$ 1,000
Common Stock [Member] \| Subsequent Event [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of shares issued, additional				3,331,771
Received from payment of fees				$ 4,675,000
Lucid Diagnostics Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock shares issued									42,329,864
Common stock shares outstanding									42,329,864
Partners capital account units acquisitions									31,302,420
Sale of stock, transaction value									$ 300,000
Sale of stock, sold									230,068
Sale of stock, commission percenatge									3.00%
Lucid Diagnostics Inc [Member] \| Subsequent Event [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock, dividends shares			3,331,747		38
Lucid Diagnostics Inc [Member] \| Maximum [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Sale of stock, transaction value								$ 6,500,000
Lucid Diagnostics Inc [Member] \| Common Stock [Member] \| Subsequent Event [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of shares issued, additional					100
Veris Health Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock shares outstanding									8,000,000

Preferred Stock

12 Months Ended

Dec. 31, 2023

Equity [Abstract]

Preferred Stock

Note 15 — Preferred Stock

As of December 31, 2023 and December 31, 2022, there were 1,305,213 and 1,205,759 shares of PAVmed Series B Convertible Preferred Stock, classified in permanent equity, issued and outstanding, respectively.

PAVmed Series B Convertible Preferred Stock Dividends

The Series B Convertible Preferred Stock is issued pursuant to the PAVmed Inc. Certificate of Designation of Preferences, Rights, and Limitations of Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock Certificate of Designation”), has a par value of $0.001 per share, no voting rights, a stated value of $3.00 per share, and was immediately convertible upon its issuance. At the holders’ election, fifteen shares of Series B Convertible Preferred Stock are currently convertible into one share of common stock of the Company, subject to further adjustment for the effect of future stock dividends, stock splits or similar events affecting the Company’s common stock. The Series B Convertible Preferred Stock shall not be redeemed for cash and under no circumstances shall the Company be required to net cash settle the Series B Convertible Preferred Stock.

The PAVmed Inc. Series B Convertible Preferred Stock dividends are 8.0% per annum based on the $3.00 per share stated value of the Series B Convertible Preferred Stock, with such dividends compounded quarterly, accumulate, and are payable in arrears upon being declared by the Company’s board of directors. Such dividends may be settled, at the discretion of the board of directors, through any combination of the issue of additional shares of Series B Convertible Preferred Stock, the issue shares of common stock of the Company, and /or cash payment.

PAVmed Series B Convertible Preferred Stock Dividends Earned

The Series B Convertible Preferred Stock dividends earned are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each of the respective corresponding periods presented in the accompanying consolidated statement of operations, inclusive of $304 of such dividends earned in the year ended December 31, 2023; and $281 of such dividends earned in the year ended December 31, 2022.

PAVmed Series B Convertible Preferred Stock Dividends Declared

During the year ended December 31, 2023, the Company’s board of directors declared an aggregate of approximately $298 of Series B Convertible Preferred Stock dividends, earned as of December 31, 2022; March 31, 2023; June 30, 2023; and September 30, 2023, which have been settled by the issue of an additional aggregate 99,454 shares of Series B Convertible Preferred Stock.

During the year ended December 31, 2022, the Company’s board of directors declared an aggregate of approximately $276 of Series B Convertible Preferred Stock dividends, earned as of December 31, 2021; March 31, 2022; June 30, 2022; and September 30, 2022, which have been settled by the issue of an additional aggregate 91,885 shares of Series B Convertible Preferred Stock.

Subsequent to December 31, 2023, in January 2024, the Company’s board of directors declared a PAVmed Series B Convertible Preferred Stock dividend, earned as of December 31, 2023, of $78, to be settled by the issue of 26,123 additional shares of Series B Convertible Preferred Stock.

The PAVmed Series B Convertible Preferred Stock dividends are recognized as a dividend payable liability only upon the dividend being declared payable by the Company’s board of directors. Accordingly, the dividends declared payable subsequent to the date of the accompanying consolidated balance sheet were not recognized as a dividend payable liability as the Company’s board of directors had not declared the dividends payable as of each such date.

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
U.S. federal statutory rate	21.00%	21.00%
U.S. state and local income taxes, net of federal benefit	6.10%	6.60%
Permanent differences	(2.70%)	(1.00%)
Tax credits	2.20%	1.30%
Revaluation of state deferred taxes		(15.20%)
Federal deferred true-up	5.80%
State deferred true-up	13.20%
Valuation allowance	(45.60%)	(12.70%)
Effective tax rate

The Company

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

Note 1 — The Company

Description of the Business

PAVmed is structured to be a multi-product life sciences company organized to advance a pipeline of innovative healthcare technologies. Led by a team of highly skilled personnel with a track record of bringing innovative products to market, PAVmed is focused on innovating, developing, acquiring, and commercializing novel products that target unmet needs with large addressable market opportunities. Leveraging our corporate structure—a parent company that will establish distinct subsidiaries for each financed asset—we have the flexibility to raise capital at the PAVmed level to fund product development, or to structure financing directly into each subsidiary in a manner tailored to the applicable product, the latter of which is our current strategy given prevailing market conditions.

Our current focus is multi-fold. We continue to pursue commercial expansion and execution of EsoGuard, which is the flagship product of our majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”). In addition, through a separate majority-owned subsidiary, Veris Health (“Veris”), we are focused on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Platform. In terms of other existing products and technologies, we have adopted an incubator-type platform where we are looking to obtain financing on a product-by-product basis as necessary to advance each asset to a meaningful inflection point along its path to commercialization. Finally, as resources permit, we will continue to explore external innovations that fulfill our project selection criteria without limiting ourselves to any target sector, specialty or condition.

Schedule of Income Tax (Benefit) Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal, State and Local
Federal	(16,789)	(24,265)
State and Local	(19,323)	11,124
Current and Deferred tax (benefit) expense	(36,112)	(13,141)
Less: Valuation allowance reserve	36,112	13,141
Income tax expense (benefit)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The Net loss per share - attributable to PAVmed Inc. - basic and diluted and Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows:

	2023			2022
	Years Ended December 31,
	2023			2022
Numerator
Net loss - before noncontrolling interest	$	(79,263	)	$	(103,238	)
Net loss attributable to noncontrolling interest		15,088			14,255
Net loss - as reported, attributable to PAVmed Inc.	$	(64,175	)	$	(88,983	)

Deemed dividend on Series Z warrant modification	$	(1,791	)	$	—
Series B Convertible Preferred Stock dividends – earned	$	(304	)	$	(281	)

Net loss attributable to PAVmed Inc. common stockholders	$	(66,270	)	$	(89,264	)

Denominator
Weighted average common shares outstanding, basic and diluted		7,231,546			5,938,406

Net loss per share⁽¹⁾
Basic and diluted
Net loss attributable to PAVmed Inc. common stockholders	$	(9.16	)	$	(15.03	)

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

	2023		2022
	December 31,
	2023		2022
Stock options and restricted stock awards		1,262,985		836,151
Series Z Warrants		795,830		795,830
Series B Convertible Preferred Stock		87,015		80,384
Total		2,145,830		1,712,365

Intangible Assets, net (Details Narrative) - USD ($) $ in Thousands		12 Months Ended
	Oct. 05, 2021	Dec. 31, 2023	Dec. 31, 2022
Impairment Effects on Earnings Per Share [Line Items]
Amortization of intangible assets		$ 2,021	$ 1,784
Defensive Technology [Member] \| Cap Nostics LLC [Member]
Impairment Effects on Earnings Per Share [Line Items]
Assets acquisition consideration transferred	$ 2,100
Useful life	60 months

Schedule of Fixed Assets (Details) - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Property, Plant and Equipment [Line Items]

Total Fixed Assets

$ 3,502

$ 3,259

Estimated useful life

^[1]

Less Accumulated Depreciation

$ (1,719)

(808)

Total Fixed Assets, net

1,783

2,451

Computer and Office Equipment [Member]

Property, Plant and Equipment [Line Items]

Total Fixed Assets

$ 835

784

Computer and Office Equipment [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life

2 years

Computer and Office Equipment [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life

5 years

Laboratory Equipment [Member]

Property, Plant and Equipment [Line Items]

Total Fixed Assets

$ 2,255

2,064

Laboratory Equipment [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life

3 years

Laboratory Equipment [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life

7 years

Furniture and Fixtures [Member]

Property, Plant and Equipment [Line Items]

Total Fixed Assets

$ 394

379

Furniture and Fixtures [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life

3 years

Furniture and Fixtures [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life

5 years

Leasehold Improvements [Member]

Property, Plant and Equipment [Line Items]

Total Fixed Assets

$ 2

Asset under Construction [Member]

Property, Plant and Equipment [Line Items]

Total Fixed Assets

$ 16

$ 30

[1]	Lesser of remaining lease term or estimated useful life.

Schedule of Estimated Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 688
2025	421
2026	315
Total	$ 1,424	$ 3,445

Stock-Based Compensation

12 Months Ended

Dec. 31, 2023

Retirement Benefits [Abstract]

Stock-Based Compensation

Note 14 — Stock-Based Compensation

PAVmed Inc. 2014 Long-Term Incentive Equity Plan

The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the “PAVmed 2014 Equity Plan”) is designed to enable PAVmed to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of PAVmed. The types of awards that may be granted under the PAVmed 2014 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the PAVmed compensation committee.

A total of 1,403,518 shares of common stock of PAVmed are reserved for issuance under the PAVmed 2014 Equity Plan, with 77,518 shares available for grant as of December 31, 2023. The share reservation is not diminished by a total of 66,723 PAVmed Inc. stock options and restricted stock awards granted outside the PAVmed 2014 Equity Plan as of December 31, 2023. In January 2024, the number of shares available for grant was increased by 432,452 in accordance with the evergreen provisions of the plan.

Note 14 — Stock-Based Compensation - continued

PAVmed Stock Options

PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows:

	Number of Stock Options			Weighted Average Exercise Price		Remaining Contractual Term (Years)		Intrinsic Value⁽²⁾
Outstanding stock options at December 31, 2021⁽⁴⁾		581,833		$	50.86		6.8	$	3,516
Granted⁽¹⁾		320,252		$	22.87
Exercised		(19,998	)	$	15.11
Forfeited		(110,934	)	$	47.15
Outstanding stock options at December 31, 2022⁽⁴⁾		771,153		$	40.70		7.4	$	—
Granted⁽¹⁾		576,975		$	6.87
Exercised		—		$	—
Forfeited		(155,670	)	$	26.51
Outstanding stock options at December 31, 2023⁽³⁾		1,192,458		$	26.18		7.3	$	—
Vested and exercisable stock options at December 31, 2023		722,039		$	35.82		6.4	$	—

⁽¹⁾	Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.
⁽²⁾	The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of December 31, 2023 and December 31, 2022 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price.
⁽³⁾	The outstanding stock options presented in the table above, are inclusive of 60,057 and 33,391, stock options granted outside the PAVmed 2014 Equity Plan, as of December 31, 2023 and December 31, 2022, respectively.
⁽⁴⁾	Share activity and weighted average grant date fair values include immaterial rounding due to the Company’s 1-for-15 reverse stock split.

Subsequent to December 31, 2023, on February 22, 2024, the Company granted 59,500 stock options under the PAVmed Inc 2014 Equity Plan with a weighted average exercise price of $1.85 for which will generally vest one-third after one year then ratably over the next eight quarters. In addition, on February 22, 2024, a total of 390,000 restricted stock awards were granted to the Board of Directors under the PAVmed 2014 Equity Plan, with such restricted stock awards having an aggregate fair value of approximately $0.7 million, which was measured using the respective grant date quoted closing price per share of PAVmed Inc. common stock, with the fair value recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The vesting of the restricted stock awards vest ratably on an annual basis over a three year period with the initial annual vesting date of November 30, 2024. The restricted stock awards are subject to forfeiture if the requisite service period is not completed.

PAVmed Restricted Stock Awards

PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows:

	Number of Restricted Stock Awards			Weighted Average Grant Date Fair Value
Outstanding restricted stock awards as of December 31, 2021⁽²⁾		111,109		$	35.40
Granted		—		$	—
Vested		(36,111	)	$	17.94
Forfeited		(10,000	)	$	30.60
Unvested restricted stock awards as of December 31, 2022⁽¹⁾		64,998		$	45.76
Granted